Heparin binding protein in patients with acute respiratory failure treated with granulocyte colony-stimulating factor (filgrastim)--a prospective, placebo-controlled, double-blind study

Kirsi-Maija Kaukonen, Heiko Herwald, Lennart Lindbom, Ville Pettila, Kirsi-Maija Kaukonen, Heiko Herwald, Lennart Lindbom, Ville Pettila

Abstract

Background: Heparin Binding Protein (HBP) is released to blood circulation from activated neutrophils in bacterial infections. It is a potential inducer of vascular leakage and precludes the development of septic shock. Filgrastim induces the production of new neutrophils and modulates their bacterial-killing activity. We evaluated the effect of filgrastim on HBP -concentrations in critically ill patients with acute respiratory failure.

Methods: 59 critically ill patients with acute respiratory failure were included in this randomised, double-blind, placebo-controlled study of filgrastim 300 micrograms/day or corresponding placebo for 7 days. Plasma samples were drawn on baseline, day 4 and day 7. HBP -concentrations, absolute leukocyte and neutrophil counts were measured.

Results: The median [IQR] HBP concentrations were 23.6 ng/ml [13.9-43.0 ng/ml], 25.1 ng/ml [17.7-35.5 ng/ml] and 15.9 ng/ml [12.6-20.7 ng/ml] in patients receiving filgrastim on baseline, day 4 and day 7, respectively. The HBP concentrations in placebo group were 21.6 ng/ml [16.9-28.7 ng/ml], 13.9 ng/ml [12.0-19.5 ng/ml] and 17.8 ng/ml [13.6-20.9 ng/ml]. At day 4, the filgrastim group had significantly higher HBP -concentrations when compared to placebo group (p < 0.05). No correlation between HBP-concentrations and absolute neutrophil count or P/F -ratios was found.

Conclusions: Filgrastim treatment is associated with increased circulating HBP levels compared to placebo, but the absolute neutrophil count or the degree of oxygenation failure did not correlate with the observed plasma HBP-concentrations.

Trial registration: ClinicalTrials.gov NCT01713309.

Figures

Figure 1
Figure 1
The concentrations (ng/ml; median, 95% CI) of HBP between patients receiving filgrastim 300 microgr/day or placebo for 7 days.
Figure 2
Figure 2
The correlation of HBP –concentrations to P/F –ratio (left panel) and absolute neutrophil count (right panel).

References

    1. Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420(6917):885–891. doi: 10.1038/nature01326.
    1. Tapper H, Karlsson A, Morgelin M, Flodgaard H, Herwald H. Secretion of heparin-binding protein from human neutrophils is determined by its localization in azurophilic granules and secretory vesicles. Blood. 2002;99(5):1785–1793. doi: 10.1182/blood.V99.5.1785.
    1. Gautam N, Olofsson AM, Herwald H, Iversen LF, Lundgren-Akerlund E, Hedqvist P, Arfors KE, Flodgaard H, Lindbom L. Heparin-binding protein (HBP/CAP37): a missing link in neutrophil-evoked alteration of vascular permeability. Nat Med. 2001;7(10):1123–1127. doi: 10.1038/nm1001-1123.
    1. Johansson J, Lindbom L, Herwald H, Sjoberg F. Neutrophil-derived heparin binding protein–a mediator of increased vascular permeability after burns? Burns. 2009;35(8):1185–1187. doi: 10.1016/j.burns.2009.02.021.
    1. Linder A, Christensson B, Herwald H, Bjorck L, Akesson P. Heparin-binding protein: an early marker of circulatory failure in sepsis. Clin Infect Dis. 2009;49(7):1044–1050. doi: 10.1086/605563.
    1. Linder A, Johansson L, Thulin P, Hertzen E, Morgelin M, Christensson B, Bjorck L, Norrby-Teglund A, Akesson P. Erysipelas caused by group A streptococcus activates the contact system and induces the release of heparin-binding protein. J Invest Dermatol. 2010;130(5):1365–1372. doi: 10.1038/jid.2009.437.
    1. Linder A, Akesson P, Inghammar M, Treutiger CJ, Linner A, Sunden-Cullberg J. Elevated plasma levels of heparin-binding protein in intensive care unit patients with severe sepsis and septic shock. Crit Care. 2012;16(3):R90. doi: 10.1186/cc11353.
    1. Chew MS, Linder A, Santen S, Ersson A, Herwald H, Thorlacius H. Increased plasma levels of heparin-binding protein in patients with shock: a prospective, cohort study. Inflamm Res. 2012;61(4):375–379. doi: 10.1007/s00011-011-0422-6.
    1. Linko R, Okkonen M, Pettila V, Perttila J, Parviainen I, Ruokonen E, Tenhunen J, Ala-Kokko T, Varpula T. Acute respiratory failure in intensive care units. FINNALI: a prospective cohort study. Intensive Care Med. 2009;35(8):1352–1361. doi: 10.1007/s00134-009-1519-z.
    1. Linder A, Soehnlein O, Akesson P. Roles of heparin-binding protein in bacterial infections. J Innate Immun. 2010;2(5):431–438. doi: 10.1159/000314853.
    1. Kerst JM, de Haas M, van der Schoot CE, Slaper-Cortenbach IC, Kleijer M, von dem Borne AE, van Oers RH. Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood. 1993;82(11):3265–3272.
    1. Linder A, Akesson P, Brink M, Studahl M, Bjorck L, Christensson B. Heparin-binding protein: a diagnostic marker of acute bacterial meningitis. Crit Care Med. 2011;39(4):812–817. doi: 10.1097/CCM.0b013e318206c396.
    1. Pettila V, Takkunen O, Varpula T, Markkola A, Porkka K, Valtonen V. Safety of granulocyte colony-stimulating factor (filgrastim) in intubated patients in the intensive care unit: interim analysis of a prospective, placebo-controlled, double-blind study. Crit Care Med. 2000;28(11):3620–3625. doi: 10.1097/00003246-200011000-00011.
    1. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–829. doi: 10.1097/00003246-198510000-00009.
    1. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23(10):1638–1652. doi: 10.1097/00003246-199510000-00007.
    1. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707–710. doi: 10.1007/BF01709751.
    1. Takala A, Pettila V, Takkunen O, Rintala E, Kautiainen H, Repo H. Granulocyte colony-stimulating factor therapy and systemic inflammation in critically ill patients. Inflamm Res: official journal of the European Histamine Research Society [et al.] 2005;54(4):180–185. doi: 10.1007/s00011-005-1340-2.
    1. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1) N Engl J Med. 1992;327(1):28–35. doi: 10.1056/NEJM199207023270106.
    1. Soehnlein O, Oehmcke S, Ma X, Rothfuchs AG, Frithiof R, van Rooijen N, Morgelin M, Herwald H, Lindbom L. Neutrophil degranulation mediates severe lung damage triggered by streptococcal M1 protein. Eur Respir J. 2008;32(2):405–412. doi: 10.1183/09031936.00173207.
    1. Root RK, Lodato RF, Patrick W, Cade JF, Fotheringham N, Milwee S, Vincent JL, Torres A, Rello J, Nelson S. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med. 2003;31(2):367–373. doi: 10.1097/01.CCM.0000048629.32625.5D.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel